Please use this identifier to cite or link to this item:
|Title:||Design of phase I and II clinical trials in oncology and ethical issues involved||Authors:||Goh, B.C.||Keywords:||Cytotoxics development
|Issue Date:||Sep-2000||Citation:||Goh, B.C. (2000-09). Design of phase I and II clinical trials in oncology and ethical issues involved. Annals of the Academy of Medicine Singapore 29 (5) : 588-597. ScholarBank@NUS Repository.||Abstract:||Introduction: There are 2 broad classes of anticancer drugs that require different approaches to development. The classical cytotoxic agents have low therapeutic indices and therefore traditionally have different developmental strategies from non-oncology agents. The newer anticancer agents that target the signal transduction pathway and antiangiogenesis pathway have characteristics similar to non-oncology agents and will change the paradigm for drug development in oncology. Methods: To review the issues involved in phase I and II cancer trials, and to describe how these issues have been addressed. Results and Conclusions: There are significant scientific and ethical issues in phase I and II cancer clinical trials, which influence the design of these studies. Nonetheless, these trials are vital for the successful development of anticancer agents. The development of novel anticancer agents that target signal transduction and antiangiogenesis has posed great challenges, and changes in the conventional cytotoxic paradigm of development are expected for these agents.||Source Title:||Annals of the Academy of Medicine Singapore||URI:||http://scholarbank.nus.edu.sg/handle/10635/129611||ISSN:||03044602|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 11, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.